+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia



Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia



Journal of the National Comprehensive Cancer Network 17(3): 211-219



ABSTRACTBackground: Current guidelines recommend hydroxyurea (HU) as frontline therapy for patients with high-risk essential thrombocythemia (ET) to prevent thrombosis. However, little is known about the impact of HU on thrombosis or survival among these patients in the real-world setting. A retrospective cohort study was conducted of older adults (aged ≥66 years) diagnosed with ET from 2007 through 2013 using the linked SEER-Medicare database. Multivariable Cox proportional hazards regression models were used to assess the effect of HU on overall survival, and multivariable competing risk models were used to assess the effect of HU on the occurrence of thrombotic events. Of 1,010 patients, 745 (73.8%) received HU. Treatment with HU was associated with a significantly lower risk of death (hazard ratio [HR], 0.52; 95% CI, 0.43-0.64; P<.01). Every 10% increase in HU proportion of days covered was associated with a 12% decreased risk of death (HR, 0.88; 95% CI, 0.86-0.91; P<.01). Compared with nonusers, HU users also had a significantly lower risk of thrombotic events (HR, 0.51; 95% CI, 0.41-0.64; P<.01). Although underused in our study population, HU was associated with a reduced incidence of thrombotic events and improved overall survival in older patients with ET.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066584718

Download citation: RISBibTeXText

PMID: 30865915


Related references

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medicine 332(17): 1132-1136, 1995

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2(20): 2681-2690, 2018

Hydroxyurea for the treatment of patients with essential thrombocythemia and high-risk of thrombosis A prospective, randomized trial. Blood 84(10 Suppl. 1): 517A, 1994

Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 101(9): 3749, 2003

Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients. Medicina Clinica 144(6): 247-253, 2015

The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis. International Journal of Hematology 102(2): 170-180, 2015

Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Annals of Hematology 90(8): 933-938, 2011

Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. American Journal of Hematology 89(5): 542-546, 2014

Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Annals of Hematology 78(12): 539-543, 1999

Acute leukemia in essential thrombocythemia The impact of hydroxyurea. British Journal of Haematology 93(Suppl. 2): 236, 1996

Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. International Journal of Hematology 75(4): 394-400, 2002

Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 115(24): 5740-5745, 2009

Clinical characteristics and risk factors for major thrombosis in 604 Chinese patients with low-risk essential thrombocythemia. Zhonghua Xue Ye Xue Za Zhi 35(9): 785-790, 2014

Risk factors for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia. Zhonghua Xue Ye Xue Za Zhi 40(1): 17-23, 2019

The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia. Medical Oncology 31(10): 231, 2014